Bessemer Group Inc. Purchases 93,100 Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI)

Share on StockTwits

Bessemer Group Inc. increased its position in shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) by 60.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 247,300 shares of the specialty pharmaceutical company’s stock after buying an additional 93,100 shares during the quarter. Bessemer Group Inc. owned about 0.28% of BioDelivery Sciences International worth $1,563,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Northern Trust Corp grew its holdings in shares of BioDelivery Sciences International by 39.8% during the second quarter. Northern Trust Corp now owns 258,748 shares of the specialty pharmaceutical company’s stock valued at $1,203,000 after buying an additional 73,637 shares during the last quarter. Vanguard Group Inc. raised its position in shares of BioDelivery Sciences International by 30.5% in the second quarter. Vanguard Group Inc. now owns 3,395,428 shares of the specialty pharmaceutical company’s stock valued at $15,788,000 after purchasing an additional 793,179 shares during the period. Nuveen Asset Management LLC purchased a new stake in shares of BioDelivery Sciences International during the 2nd quarter valued at approximately $2,358,000. Nisa Investment Advisors LLC purchased a new stake in shares of BioDelivery Sciences International during the 3rd quarter valued at approximately $148,000. Finally, NEXT Financial Group Inc boosted its holdings in BioDelivery Sciences International by 15.1% in the 3rd quarter. NEXT Financial Group Inc now owns 155,850 shares of the specialty pharmaceutical company’s stock worth $656,000 after buying an additional 20,500 shares during the period. 68.50% of the stock is currently owned by institutional investors and hedge funds.

In related news, insider Scott M. Plesha sold 25,000 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $6.21, for a total transaction of $155,250.00. Also, CEO Herm Cukier sold 31,850 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $5.16, for a total value of $164,346.00. Following the transaction, the chief executive officer now owns 67,631 shares of the company’s stock, valued at $348,975.96. The disclosure for this sale can be found here. Over the last three months, insiders sold 4,001,613 shares of company stock valued at $24,653,415. Insiders own 8.94% of the company’s stock.

BDSI has been the subject of a number of recent research reports. LADENBURG THALM/SH SH lifted their price objective on shares of BioDelivery Sciences International from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Janney Montgomery Scott restated a “buy” rating on shares of BioDelivery Sciences International in a research report on Wednesday, November 13th. BidaskClub lowered BioDelivery Sciences International from a “sell” rating to a “strong sell” rating in a report on Friday, January 31st. ValuEngine raised BioDelivery Sciences International from a “sell” rating to a “hold” rating in a report on Saturday, February 1st. Finally, SunTrust Banks lifted their price target on BioDelivery Sciences International from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $7.75.

Shares of BioDelivery Sciences International stock opened at $5.27 on Friday. The company’s 50-day moving average price is $5.69 and its 200-day moving average price is $5.33. The company has a current ratio of 2.25, a quick ratio of 2.02 and a debt-to-equity ratio of 0.86. BioDelivery Sciences International, Inc. has a 12-month low of $3.59 and a 12-month high of $7.21. The company has a market cap of $471.79 million, a price-to-earnings ratio of -18.82 and a beta of 0.52.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings data on Tuesday, November 12th. The specialty pharmaceutical company reported $0.33 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.34. BioDelivery Sciences International had a negative net margin of 22.11% and a negative return on equity of 8.80%. The company had revenue of $30.31 million during the quarter, compared to analysts’ expectations of $28.86 million. On average, sell-side analysts predict that BioDelivery Sciences International, Inc. will post 0.02 earnings per share for the current year.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Further Reading: What does the Dogs of the Dow mean?

Want to see what other hedge funds are holding BDSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioDelivery Sciences International, Inc. (NASDAQ:BDSI).

Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Southern National Banc. of Virginia  Downgraded by BidaskClub
Southern National Banc. of Virginia Downgraded by BidaskClub
Stemline Therapeutics  Raised to Hold at BidaskClub
Stemline Therapeutics Raised to Hold at BidaskClub
Shotspotter  Price Target Increased to $41.00 by Analysts at Imperial Capital
Shotspotter Price Target Increased to $41.00 by Analysts at Imperial Capital
Shotspotter  Upgraded at Zacks Investment Research
Shotspotter Upgraded at Zacks Investment Research
ValuEngine Upgrades SP Plus  to “Sell”
ValuEngine Upgrades SP Plus to “Sell”
SP Plus  PT Lowered to $52.00 at Sidoti
SP Plus PT Lowered to $52.00 at Sidoti


 
© 2006-2020 Zolmax.